Geron (NASDAQ:GERN) Issues Earnings Results

Geron (NASDAQ:GERN) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05, Briefing.com reports. The firm had revenue of $28.27 million for the quarter, compared to analysts’ expectations of $18.97 million. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The company’s revenue for the quarter was up 17138.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.08) earnings per share.

Geron Stock Performance

GERN stock traded down $0.07 during midday trading on Friday, reaching $4.22. 6,805,310 shares of the company’s stock traded hands, compared to its average volume of 10,438,124. The company has a current ratio of 3.61, a quick ratio of 3.60 and a debt-to-equity ratio of 0.12. Geron has a 52-week low of $1.64 and a 52-week high of $5.34. The stock has a market cap of $2.54 billion, a P/E ratio of -11.92 and a beta of 0.52. The stock’s 50-day moving average is $4.32 and its 200 day moving average is $4.30.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Leerink Partners began coverage on Geron in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price objective for the company. StockNews.com upgraded shares of Geron to a “sell” rating in a report on Monday, August 5th. Wedbush reiterated an “outperform” rating and set a $8.00 price target on shares of Geron in a research report on Thursday, August 8th. HC Wainwright assumed coverage on shares of Geron in a report on Tuesday. They issued a “buy” rating and a $8.00 price objective for the company. Finally, Leerink Partnrs raised Geron to a “strong-buy” rating in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.05.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.